SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bioinformatics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (74)1/29/2007 4:07:52 PM
From: Mike McFarland   of 80
 
Here is the article that mentioned Eidogen-Sertanty
"In the interest of advancing the field, pharmaceutical companies need to share the already available data," says Joe Votano, president of R&D at ChemSilico, Tewksbury, Mass. Steve Muskal, CEO of San Diego, Calif.-based Sertanty, agrees. The more powerful models could improve both the predictive power of the models as well as save time and resources, according to Muskal. Both ChemSilico and Sertanty are involved in developing software to aid drug discovery.

from
The Delicate Toxicity Balance in Drug Discovery
Can pricey late-stage failures – or dangerous drugs – be prevented with better products for predicting drug toxicity?
Email: Usha Sankar - usankar@the-scientist.com
The Scientist 2005, 19(15):32
the-scientist.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News